Ralph Loren, an intellectual property partner in Edwards Wildman's Boston office, was cited in Law360
's coverage of the likelihood that the US Supreme Court will decide if breast cancer genes isolated by Myriad Genetics Inc. are patent-eligible subject matter. In "Justices Expected To Write Final Chapter On Gene Patents
,” Loren noted that the patentability of human genes is of critical importance to the biotechnology industry, so it would be surprising if the Supreme Court did not take the case and articulate a definitive statement on the issue. "They almost have to take the case," said Loren. "They could deny cert, but I don't think so. Too many people are interested in it."